Evidence map›Paper›PMID 42706177›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026

[Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia].

D D Chen, J C Xu, Z Yin, P C Shi, D Xu, J Y Ye, H Liu, L Xuan, Y Zhang, Q F Liu and 1 more

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

D D ChenDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J C XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Z YinDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
P C ShiDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
D XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J Y YeDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
H LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
L XuanDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Y ZhangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Q F LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
G P YuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China Department of Hematology, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou 510317, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the real-world application of ivosidenib (IVO) in patients with IDH1-mutated acute myeloid leukemia (AML), as well as its efficacy and safety. We retrospectively analyzed clinical data from 16 patients with IDH1-mutated AML who received IVO-based therapy at Nanfang Hospital between September 2021 and May 2025. The median age was 57 years (range, 25 - 80 years), with 7 males and 9 females. Six patients (37.5%) had an Eastern Cooperative Oncology Group performance status of 3 - 4, and 14 patients (87.5%) were classified as intermediate- or high-risk according to the European LeukemiaNet criteria. Among 5 patients (31.2%) receiving venetoclax (VEN) plus azacitidine (AZA) combined with IVO for induction, 3 achieved complete remission (CR), including 2 with measurable residual disease (MRD) -negative and IDH1 dPCR-negative status. Two patients (12.5%) received VA plus IVO for consolidation; both maintained CR, with 1 achieving MRD-negative and IDH1 dPCR-negative status. Four relapsed or refractory patients (25.0%) received VEN plus hypomethylating agents (HMA) combined with IVO (

Indexed as

GlycineLeukemia, Myeloid, AcutePyridinesAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansIsocitrate DehydrogenaseMaleMiddle AgedMutationRetrospective StudiesTreatment OutcomeGlycineIDH1 protein, humanIsocitrate DehydrogenaseivosidenibPyridines

Identifiers

PMID42706177
PMCPMC13575527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.